PDL BioPharma Shares Outstanding 2010-2020 | PDLI

PDL BioPharma shares outstanding from 2010 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
PDL BioPharma Annual Shares Outstanding
(Millions of Shares)
2020
2019 119
2018 146
2017 156
2016 164
2015 164
2014 173
2013 159
2012 146
2011 177
2010 179
2009 184
PDL BioPharma Quarterly Shares Outstanding
(Millions of Shares)
2020-12-31
2020-06-30 116
2020-03-31 123
2019-12-31 119
2019-09-30 113
2019-06-30 118
2019-03-31 129
2018-12-31 146
2018-09-30 144
2018-06-30 147
2018-03-31 153
2017-12-31 156
2017-09-30 152
2017-06-30 156
2017-03-31 164
2016-12-31 164
2016-09-30 164
2016-06-30 164
2016-03-31 164
2015-12-31 164
2015-09-30 164
2015-06-30 165
2015-03-31 170
2014-12-31 173
2014-09-30 167
2014-06-30 177
2014-03-31 165
2013-12-31 159
2013-09-30 155
2013-06-30 152
2013-03-31 149
2012-12-31 146
2012-09-30 150
2012-06-30 142
2012-03-31 140
2011-12-31 177
2011-09-30 167
2011-06-30 186
2011-03-31 190
2010-12-31 179
2010-09-30 172
2010-06-30 173
2010-03-31 184
2009-12-31 184
2009-09-30 169
2009-06-30 170
2009-03-31 173
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.000B $0.055B
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00